RT Journal Article
SR Electronic
T1 Interest of circulating tumor DNA as a biomarker for canine cancers: illustration in histiocytic sarcoma, oral malignant melanoma and multicentric lymphoma
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.07.10.189118
DO 10.1101/2020.07.10.189118
A1 Anaïs Prouteau
A1 Jérôme Alexandre Denis
A1 Pauline De Fornel
A1 Edouard Cadieu
A1 Thomas Derrien
A1 Camille Kergal
A1 Nadine Botherel
A1 Ronan Ulvé
A1 Mélanie Rault
A1 Amira Bouzidi
A1 Romain François
A1 Laetitia Dorso
A1 Alexandra Lespagnol
A1 Patrick Devauchelle
A1 Jérôme Abadie
A1 Catherine André
A1 Benoît Hédan
YR 2020
UL http://biorxiv.org/content/early/2020/07/11/2020.07.10.189118.abstract
AB Circulating tumor DNA (ctDNA) has become an attractive biomarker in human oncology and may be informative in cancer-affected dogs. By performing ddPCR or PARR methods, we detected tumor-specific point mutations, copy number alterations and chromosomal rearrangements in the plasma of cancer-affected dogs. It allowed the detection of ctDNA in 2/8 (25%) oral malignant melanoma cases, 12/13 (92.3%) lymphoma cases and 21/23 (91.3%) histiocytic sarcoma (HS) cases. The value of ctDNA to diagnose HS was explored in 133 dogs including 49 with HS. In this cohort, screening recurrent PTPN11 mutations in plasma had a specificity of 98.8%, and a sensitivity between 42.8-77% according to HS clinical presentation, being higher in internal forms, especially with pulmonary location. Regarding lymphoma, the follow-up of four dogs showed that the minimal residual disease detection by targeting lymphoma-specific antigen receptor rearrangement in the plasma was concordant with the clinical evaluation. Moreover, ctDNA analysis appeared interesting to assess treatment response and to predict relapse.This study shows that ctDNA is detectable in the plasma of cancer-affected dogs and is a relevant biomarker for diagnosis and clinical follow-up. With a growing interest in integrating natural canine tumors to explore new therapies, this biomarker appears promising in comparative oncology research.Competing Interest StatementThe authors have declared no competing interest.